Aptevo Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Aptevo Therapeutics yıllık ortalama 32% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 7.7% annual. Gelirler azalıyor .

Anahtar bilgiler

32.0%

Kazanç büyüme oranı

57.3%

EPS büyüme oranı

Biotechs Sektör Büyümesi	-14.6%
Gelir büyüme oranı	-26.8%
Özkaynak getirisi	-447.5%
Net Marj	n/a
Son Kazanç Güncellemesi	31 Mar 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Aptevo Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

DB:AP8 Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Mar 24	0	-27	11
31 Dec 23	0	-19	12
30 Sep 23	0	-18	12
30 Jun 23	0	-19	13
31 Mar 23	0	17	14
31 Dec 22	3	7	14
30 Sep 22	7	6	14
30 Jun 22	10	6	14
31 Mar 22	13	-30	15
31 Dec 21	12	-29	15
30 Sep 21	11	-30	16
30 Jun 21	9	-30	16
31 Mar 21	7	-29	14
31 Dec 20	4	-31	14
30 Sep 20	2	-33	13
30 Jun 20	0	-37	14
31 Mar 20	0	-41	15
31 Dec 19	0	-43	16
30 Sep 19	6	-48	19
30 Jun 19	12	-49	22
31 Mar 19	19	-52	25
31 Dec 18	23	-54	28
30 Sep 18	20	-49	30
30 Jun 18	20	-34	31
31 Mar 18	17	-35	32
31 Dec 17	15	-33	35
30 Sep 17	15	-39	34
30 Jun 17	11	-115	38
31 Mar 17	4	-119	37
31 Dec 16	10	-120	36
30 Sep 16	15	-122	42
30 Jun 16	19	-61	39
31 Mar 16	30	-61	43
31 Dec 15	34	-59	43
31 Dec 14	46	-51	34
31 Dec 13	0	-53	15

Kaliteli Kazançlar: AP8 şu anda kârlı değil.

Büyüyen Kar Marjı: AP8 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AP8 kârlı değildir, ancak son 5 yılda zararlarını yılda 32% oranında azaltmıştır.

Büyüme Hızlandırma: AP8 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: AP8 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -18.2% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: AP8 hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -447.5% ) sahiptir.

Aptevo Therapeutics Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2022 earnings released: EPS: US$1.38 (vs US$6.27 loss in FY 2021)

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: US$5.55 (vs US$1.78 loss in 2Q 2021)

First quarter 2022 earnings released: US$1.60 loss per share (vs US$1.74 loss in 1Q 2021)

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Recent updates

Aptevo Therapeutics Expands on the Potential of Mipletamig

Aptevo Therapeutics (Aptevo) and Alligator Bioscience AB Announce Preliminary Data from Its Phase 1 Trial Evaluating the First-In-Class Bispecific Antibody, ALG.APV-527

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2.999493 million.

Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study

Alligator Bioscience AB (publ) and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV- 527 Monotherapy in Multiple Solid Tumor Types At ESMO Congress 2024

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Aptevo Therapeutics Inc. Announces That Phase 1B/2 "Rainier" Frontline Acute Myeloid Leukemia (Aml) Trial Initiated

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Nasdaq Listing Rule 5550(a)(2)

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $2 million.

Aptevo Therapeutics Inc., Annual General Meeting, Jun 07, 2024

Aptevo Therapeutics Inc. has completed a Follow-on Equity Offering in the amount of $4.589753 million.

Aptevo Therapeutics Inc. Provides Pipeline Update

Aptevo Therapeutics Inc. has filed a Follow-on Equity Offering.

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Aptevo Therapeutics Announces 1-For 44 Reverse Stock Split as Part of Nasdaq Compliance Plan

New major risk - Revenue and earnings growth

Aptevo Therapeutics Receives Non-Compliance Letter from the Staff of the Nasdaq Stock Market

New minor risk - Profitability

Aptevo Therapeutics Inc. Announces Positive Duration of Remission Data from Phase 1B Expansion Trial Evaluating the Bispecific APVO436 for AML

New major risk - Share price stability

New major risk - Shareholder dilution

New major risk - Market cap size

Full year 2022 earnings released: EPS: US$1.38 (vs US$6.27 loss in FY 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Aptevo Therapeutics Inc. Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate (CBR) in Venetoclax Treatment Naïve AML Patients

Investor sentiment improved over the past week

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$1.53 loss per share (vs US$1.45 loss in 3Q 2021)

Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics

Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: US$5.55 (vs US$1.78 loss in 2Q 2021)

Forecast to breakeven in 2022

Emergent Biosolutions Inc. Appoints Sujata Dayal as A Class II Director to Serve on the Board Effective July 15, 2022 and Member of Both the Nominating and Corporate Governance Committee and the Special Committee on Manufacturing and Quality Oversight

Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

First quarter 2022 earnings released: US$1.60 loss per share (vs US$1.74 loss in 1Q 2021)

Insufficient new directors

Aptevo Therapeutics Receives Non-Compliance Letter from Nasdaq

Aptevo Therapeutics Inc. Announces A Clinical Update for the Phase 1B Expansion Trial Evaluating Apvo436 in the Treatment of Acute Myeloid Leukemia

Third quarter 2021 earnings released: US$1.45 loss per share (vs US$2.15 loss in 3Q 2020)

Insufficient new directors

Tang Capital Partners, LP along with Tang Capital Management, LLC cancelled the acquisition of remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) on June 21, 2021.

Tang Capital Withdraws its Proposals to Aptevo Therapeutics

Aptevo Therapeutics Inc. Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults with Relapsed Acute Myeloid Leukemia

Aptevo Therapeutics, Inc. Enters into an Llc Purchase Agreement with Medexus Pharma, Inc

Aptevo Therapeutics Inc. Expands its ADAPTIR Bispecific Platform Technology to Include a New Multi-Specific Platform Technology, ADAPTIR-FLEX

Tang Capital Partners, LP along with Tang Capital Management, LLC made a bid to acquire remaining 57.5% stake in Aptevo Therapeutics Inc. (NasdaqCM:APVO) for approximately $120 million.

Aptevo Therapeutics and Alligator Bioscience advancing the bispecific 4-1BBx5T4 antibody ALG.APV-527 into Phase I clinical development

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin